Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지

Role of B-type Natriuretic Peptide in Diagnosis and Follow-up of Diastolic Heart Failure

이완기 심부전증의 진단 및 경과 관찰에서 B-type Natriuretic Peptide의 역할

Kang, Duk-Hyun;Kim, Mi-Jeong;Kang, Soo-Jin;Kim, Young-Hak;Song, Jong-Min;Song, Jae-Kwan;Kim, Jae-Joong
강덕현;김미정;강수진;김영학;송종민;송재관;김재중

  • Published : 20060000
⟨ Previous Next ⟩

Abstract

Background and Objectives：Although Doppler echocardiography has been used to identify left ventricular (LV) diastolic dysfunction, its limitations suggest there is a need for new biomarkers to measure the diastolic dysfunction. Because the B-type natriuretic peptide (BNP) levels correlate with the LV diastolic pressure, we hypothesized that the BNP would be useful for diagnosing and monitoring the patients with diastolic heart failure. Subjects and Methods：We prospectively studied a total of 69 consecutive patients (mean age: 68${\pm}$12 yrs, 31 men and 38 women) who presented to the emergency room with suspected dyspnea of a cardiac origin from November 2003 to May 2004. BNP sampling and Doppler echocardiography were performed for all the study patients. We diagnosed the systolic heart failure (SHF) and diastolic heart failure (DHF) on the conditions that both the clinical and echocardiographic criteria for systolic and diastolic dysfunction were fulfilled. From June 2004 to May 2005, we also performed clinical examinations, measurement of the tissue Doppler derived E/E’ and the BNP level at baseline and at 1 year after pharmacologic treatment for 42 consecutive patients who were diagnosed with DHF in the ER and the outpatient clinic. Results：We diagnosed SHF in 37 patients, DHF in 19 patients and we excluded HF in 13 patients (the control group). The mean BNP levels of the SHF and DHF groups were 716${\pm}$532 pg/mL and 390${\pm}$446 pg/mL, respectively, and these values were significantly higher than that of the control group (13${\pm}$14 pg/mL, p<0.01). The area under the receiver-operating characteristic (ROC) curve for BNP to diagnose DHF was 0.94 (95% CI: 0.86 to 1.02, p<0.001). We also compared the BNP levels with the E/E’ in terms of the changes of the functional status for the 42 patients suffering with DHF. After treatment, the blood pressure (BP) was significantly decreased from 162${\pm}$26/91${\pm}$15 to 141${\pm}$16/80${\pm}$12 mmHg (p<0.001), the New York Heart Association (NYHA) functional class was decreased from 2.3${\pm}$0.7 to 1.7${\pm}$0.6 (p<0.001), and the E/E’ was decreased from 15.9${\pm}$5.7 to 13.8${\pm}$5.1 (p<0.01), but there were no significant changes of the BNP levels, from 213${\pm}$404 to 208${\pm}$464 pg/mL, following treatment. Conclusion：A BNP assay is clinically useful for diagnosing DHF, and a cut-off value of BNP can be suggested for screening DHF. However, the tissue doppler derived E/E’ is the better index for monitoring changes in the functional status of DHF patients than is the BNP level. (Korean Circulation J 2006;36:359-365)¬

Keywords

References

  1. Stevenson LW, Perloff JK. The limited availability of physical signs for estimating hemodynamics in chronic heart failure. JAMA 1989;261:884-8 https://doi.org/10.1001/jama.261.6.884
  2. Mulrow CD, Lucey CR, Farnett LE. Discriminating causes of dyspnea through the clinical examination. J Gen Intern Med 1993;8:383-92 https://doi.org/10.1007/BF02600079
  3. Senni M, Rodeheffer RJ, Tribouilloy CM, et al. Use of echocardiography in the management of congestive heart failure in the community. J Am Coll Cardiol 1999;33:164-70 https://doi.org/10.1016/S0735-1097(98)00523-3
  4. Nakagawa O, Ogawa Y, Itoh H, et al. Rapid transcriptional activation and early mRNA turnover of BNP in cardiocyte hypertrophy: evidence for BNP as an 'emergency' cardiac hormone against ventricular overload. J Clin Invest 1995;96:1280-7 https://doi.org/10.1172/JCI118162
  5. Dickstein K. Natriuretic peptides in detection of heart failure. Lancet 1998;351:4
  6. Koglin J, Pehlivanli S, Schwaiblamir M, Vogeser M, Cremer P, von Scheidt W. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 2001;38:1934-41 https://doi.org/10.1016/S0735-1097(01)01672-2
  7. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide (BNP) in the diagnosis of CHF in an urgent care setting. J Am Coll Cardiol 2001;37:379-85 https://doi.org/10.1016/S0735-1097(00)01156-6
  8. Morrison KL, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A. Utility of a rapid B-natriuretic peptide (BNP) assay in differentiating CHF from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 2002;39:202-9
  9. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography: American Society of Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989;2:358-67 https://doi.org/10.1016/S0894-7317(89)80014-8
  10. Cleland JG, Tendera M, Adams J, et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. Eur J Heart Fail 1999;1:211-7 https://doi.org/10.1016/S1388-9842(99)00039-2
  11. European Study Group on Diastolic Heart Failure. How to diagnose diastolic heart failure. Eur Heart J 1998;19:990-1003 https://doi.org/10.1053/euhj.1998.1057
  12. Vasan RS, Benjamin EJ, Levy D. Prevalcence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol 1995;26:1565-74 https://doi.org/10.1016/0735-1097(95)00381-9
  13. Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community: a study of all incident cases in Olmstead County, Minnesota, in 1991. Circulation 1998;98:2282-9 https://doi.org/10.1161/01.CIR.98.21.2282
  14. Vasan RS, Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation 2000;101:2118-21 https://doi.org/10.1161/01.CIR.101.17.2118
  15. Caruana L, Petrie MC, Davie AP, McMurray JJ. Do patients with suspected heart failure and preserved left ventricular systolic function suffer from 'diastolic heart failure' or from misdiagnosis?: a prospective descriptive study. BMJ 2000;321:215-8 https://doi.org/10.1136/bmj.321.7255.215
  16. Sohn DW, Chai IH, Lee DJ, et al. Assessment of mitral annulus velocity by Doppler tissue imaging in the evaluation of left ventricular diastolic function. J Am Coll Cardiol 1997;30:474-80 https://doi.org/10.1016/S0735-1097(97)88335-0
  17. Nagueh SF, Middleton KJ, Kopelen HA, Zoghbi WA, Quinones MA. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 1997;30:1527-33 https://doi.org/10.1016/S0735-1097(97)00344-6
  18. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur Heart J 2005;26:1115-40 https://doi.org/10.1093/eurheartj/ehi204
  19. Yoo BS, Kim WJ, Jung HS, et al. The clinical experiences of Btype natriuretic peptide blood concentrations for diagnosis in congestive heart failure. Korean Circ J 2004;34:684-92 https://doi.org/10.4070/kcj.2004.34.7.684
  20. Kitzman DW, Little WC, Brubaker PH, et al. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 2002;288:2144-50 https://doi.org/10.1001/jama.288.17.2144
  21. Lubien E, DeMaria A, Krishnaswamy P, et al. Utility of Bnatriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 2002;105:595-601 https://doi.org/10.1161/hc0502.103010
  22. Mottram PM, Leano R, Marwick TH. Usefulness of B-type natriuretic peptide in hypertensive patients with exertional dyspnea and normal left ventricular ejection fraction and correlation with new echocardiographic indexes of systolic and diastolic function. Am J Cardiol 2003;92:1434-8 https://doi.org/10.1016/j.amjcard.2003.08.053
  23. Kwon SH, On YK, Han DH, et al. Usefulness of B-type natriuretic peptide in congestive heart failure. Korean Circ J 2003;33: 695-700 https://doi.org/10.4070/kcj.2003.33.8.695
  24. Shin HS, Sung KC, Jung CH, et al. B-type natriuretic peptide blood concentrations in differential diagnosis of dyspnea and its association to 6 minute walk. Korean Circ J 2003;33:302-10 https://doi.org/10.4070/kcj.2003.33.4.302
  25. Doust JA, Glasziou PP, Pietrzak E, Dobson AJ. A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. Arch Intern Med 2004;164:1978-84 https://doi.org/10.1001/archinte.164.18.1978
  26. Kostis JB, Davis BR, Cutler J, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension: SHEP Cooperative Research Group. JAMA 1997;278:212-6 https://doi.org/10.1001/jama.278.3.212
  27. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362:777-81 https://doi.org/10.1016/S0140-6736(03)14285-7